Clinical trial NCT04536792: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease
Official title: A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Subjects With Sickle Cell Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Anemia, Sickle Cell
Keywords: Sickle Cell Disease
Healthy
Lead sponsor: Agios Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2020-09-03
Enrollment: 122
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to assess the safety and tolerability of AG-946 in healthy volunteers after oral administration of single ascending doses (SAD) and multiple ascending doses (MAD) of AG-946 over 14 or up to 28 days of dosing, and to identify a range of doses that are safe and pharmacologically active in participants with sickle cell disease. The SAD and MAD parts of the study will be randomized and double-blinded, and will assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of AG-946 as well as the effect of food (SAD only) on the pharmacokinetics (PK) of AG-946. The sickle cell disease (SCD) part of the study will be non-randomized and open-label, and is designed to identify 1 or more safe and tolerable dose(s) of AG-946 with potential activity in the treatment of participants with sickle cell disease (SCD).


Eligibility criteria: Inclusion Criteria:

SAD and MAD

* Participant is a healthy male or a female of nonchildbearing potential aged 18 to 55 years inclusive at the time of consent;
* Participant is able to understand and provide informed consent before the conduct of any protocol-specific screening procedures;
* Participant is willing and able to complete all study assessments and procedures;
* Participant has a bodyweight ≥50 kilograms (kg) and body mass index ≥18.5 and ≤32 kilograms per square meter (kg/m\^2) at screening;
* Participant is in good general health with no clinically significant deviations from normal in screening medical history, physical examination, vital signs, or electrocardiogram (ECGs);
* Male participants must agree to be abstinent as part of their usual lifestyle or use contraception up to 90 days after last dose of study treatment;
* Participant is a non-smoker and has not used nicotine-containing products for at least 3 months prior to screening;
* Participant is willing to refrain from caffeine- or xanthene-containing products (eg, coffee, tea, cola, chocolate) for 48 hours before the first dose of study treatment through 7 days after the last dose of study treatment;
* Participant is willing to refrain from marijuana- or cannabinol-containing products for 7 days before admission through the final visit;
* Participant is willing to refrain from strenuous exercise starting 72 hours before admission through the final visit;
* Participant is willing to refrain from use of alcohol starting 7 days prior to admission through final visit;
* Participant agrees not to donate blood products for duration of study participation;
* Male participants must agree not to donate sperm for duration of study and for 90 days after the last dose.

Exclusion Criteria:

SAD and MAD

* Participant has previously enrolled in this study or has received an investigational drug with 3 months or 5 half-lives of the drug, whichever is longer, before the first dose of study treatment;
* Participant has previously received AG-946, except for participants who are dosing in the fed portion of the food-effect group;
* Participant has a heart rate-corrected QT interval (QTc) interval using Fridericia correction method (QTcF) \>450 milliseconds (ms) at screening;
* Participant has used over-the-counter medication (excluding routine vitamins) within 7 days of the first dose of study treatment, unless agreed as not clinically relevant;
* Participant has used acetaminophen greater than 2 grams (g) in any 24-hour period up to 48 hours before the first dose of study treatment;
* Participants has clinically relevant screening laboratory tests results outside the normal range;
* Participant has a history of any relevant cardiovascular, renal, hepatic, chronic respiratory, or gastrointestinal disease; or hematologic, lymphatic, neurologic, endocrine, psychiatric, musculoskeletal, genitourinary, immunologic, dermatologic, or connective tissue disease or disorders;
* Participant has a history of serious mental illness, that includes, but is not limited to schizophrenia, bipolar disorder, or major depression;
* Participant has a history of any primary malignancy, except for basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ or other malignancies that have been curatively treated and with no evidence of disease for at least 5 years before screening;
* Participant has had surgery within 6 months before the first dose of study treatment;
* Participant has a preexisting condition that interferes with normal gastrointestinal anatomy or motility, and/or hepatic and/or renal function that could interfere with the absorption, metabolism, and/or excretion of the study treatment or has previously undergone cholecystectomy;
* Participant has systolic blood pressure (BP) ≥140 mm Hg or a diastolic BP of ≥90 mm Hg after 10 minutes rest at screening or before the first dosing of study treatment;
* Participant has medical or psychological condition deemed by the Investigator to be likely to interfere with the volunteer's ability to provide informed consent, cooperate, and/or participate in the study;
* Participant has a known allergy to any of the excipients or components of the study treatment;
* Participant tests positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody (Ab), or human immunodeficiency virus (HIV) infection -1 or -2 Ab;
* Participant has donated blood, had blood loss of more than 500 milliliters (mL), or has received transfusion of blood or plasma within 3 months before screening;
* Participant has a history of illicit drug abuse or alcoholism within the last 1 year before screening;
* Participant has consumed more than 21 units of alcohol a week within the last 1 year before screening;
* Participant has used prescription drugs within 2 weeks or 5 half-lives (whichever is longer) before the first dose of study treatment;
* Participant has a positive screen for drugs of abuse or urinary cotinine \>200 nanograms per milliliter (ng/mL) at screening or admission; or a positive screen for alcohol (via urine analysis) at admission;
* Participant cannot communicate reliably with the Investigator;
* Participant cannot or is unlikely to cooperate with the requirements of the study;
* Participant has any conditions that, in the judgment of the Investigator, would make the volunteer unsuitable for enrollment or could interfere with the volunteer's participation in, or completion of, the study;
* Participant has known glucose-6-phosphate dehydrogenase (G6PD) deficiency or G6PD activity below the lower limit of the normal range at the screening visit.

Inclusion Criteria:

SCD

* Participant is a male or female aged 18 to 70 years inclusive at the time of consent;
* Participant has documented sickle cell anemia;
* Provided informed consent before the conduct of any protocol-specific screening procedures;
* If the participant is taking hydroxyurea (HU), L-glutamine, and/or crizanlizumab, the dose(s) must have been stable for at least 3 months before the first dose of AG-946;
* Participant must start or continue to take folic acid in the equivalent of at least 0.8 milligrams per day (mg/day) orally for the duration of the study, unless the Investigator considers dietary folic acid intake to be adequate;
* Participant has adequate organ function;
* Female participants who are of childbearing potential, must have negative pregnancy test during screening;
* Female participants who are of childbearing potential and male participants who have partners who are females of childbearing potential, must agree to be abstinent as part of their usual lifestyle or agree to use contraception from the time of providing informed consent to 28 days for women and 90 days for men after the last dose of AG-946;
* Participant must be willing to comply with all study procedures for the duration of the study.

Exclusion Criteria:

SCD

* Participant is a candidate for potentially curative treatment with bone marrow transplantation, and for whom participation in this study would delay or preclude such definitive treatment;
* Participant has documented history of pyruvate kinase deficiency (PKD) or red blood cell-specific form of pyruvate kinase (PKLR) mutation;
* Participant has had more than 6 vaso-occlusive crisis (VOCs) within the past 12 months that required a hospital, emergency room, or clinic visit;
* Participant is receiving regularly scheduled red blood cell (RBC) transfusion therapy, and/or has received a transfusion within the past 3 months before the first dose of AG-946;
* Participant is currently receiving treatment with voxelotor or any other agent intended to increase hemoglobin (Hb)-oxygen affinity;
* Participant has a significant medical condition that confers an unacceptable risk to participating in the study, and/or that could confound the interpretation of the study data as follows:

  1. Poorly controlled hypertension (defined as systolic BP \>150 millimeters of mercury (mm Hg) or diastolic BP \>90 mm Hg) refractory to medical management
  2. Any history of congestive heart failure; myocardial infarction; unstable angina pectoris; hemorrhagic, embolic, or thrombotic stroke; or recent venous thrombosis or pulmonary or arterial embolism
  3. Cardiac dysrhythmias judged as clinically significant by the Investigator
  4. QTcF \>450 milliseconds (ms), unless related to right or left bundle branch block
  5. Clinically symptomatic cholelithiasis or cholecystitis
  6. History of drug-induced cholestatic hepatitis
  7. Iron overload sufficiently severe to result in a clinical diagnosis by the Investigator of cardiac, hepatic, or pancreatic dysfunction
  8. Have a diagnosis of any other congenital or acquired blood disorder, or any other hemolytic process as defined by a positive direct antiglobulin test, except for mild alloimmunization as a consequence of transfusion therapy
  9. Positive test for HBsAg, or positive test for HCV Ab with evidence of active virus infection
  10. Positive test for HIV-1 or -2 Ab
  11. Active infection requiring the use of parenteral antimicrobial agents or Grade ≥3 in severity
  12. Diabetes mellitus judged to be under poor control by the Investigator or requiring \>2 antidiabetic agents, including insulin
  13. History of any primary malignancy, except for curatively treated nonmelanoma skin cancer, cervical or breast carcinoma in situ, prostate cancer, or other primary tumor treated with curative intent, no known active disease present, and no treatment administered during the last 3 years before Screening
  14. Unstable extramedullary hematopoiesis that could pose a risk of imminent neurologic compromise
  15. Current or recent history of a psychiatric disorder
* Participant is currently enrolled in another therapeutic clinical trial involving ongoing therapy with any investigational or marketed product or placebo;
* Participant has had exposure to any investigational drug within 3 months or 5 half-lives of the drug, whichever is longer, before the first dose of AG-946;
* Participant has had exposure to any investigational device or invasive procedure within 3 months before the first dose of AG-946;
* Participant has a history of major surgery within 6 months of providing informed consent;
* Participant has had a prior bone marrow or stem cell transplant;
* Participant is currently pregnant or breastfeeding;
* Participant has received medications that are strong inhibitors of permeability-glycoprotein (P-gp) within 5 days or a time frame equivalent to 5 half-lives (whichever is longer) before the first dose of AG-946;
* Participant has received hematopoietic stimulating agents within 28 days before the first dose of AG-946;
* Participant has a known allergy to any of the excipients found in AG-946.

Primary outcomes:
measure: SAD and MAD: Number of Participants Who Experienced at Least One Adverse Event (AE), by Severity
timeFrame: SAD: Up to Day 13; MAD: Up to Day 49
measure: SAD and MAD: Number of Participants Who Experienced at Least One AE Related to the Study Drug
timeFrame: SAD: Up to Day 13; MAD: Up to Day 49
measure: SAD and MAD: Number of Participants Who Experienced at Least One Serious Adverse Event (SAE)
timeFrame: SAD: Up to Day 13; MAD: Up to Day 49
measure: SAD and MAD: Number of Participants With Clinically Significant Laboratory Abnormalities, by Severity
timeFrame: SAD: Up to Day 13; MAD: Up to Day 49
measure: SAD and MAD: Number of Participants With Clinically Significant Changes in Vital Signs and in Electrocardiogram (ECG) Parameters
timeFrame: SAD: Up to Day 13; MAD: Up to Day 49
measure: SCD: Number of Participants Who Experienced at Least One AE, by Severity
timeFrame: Up to Day 56
measure: SCD: Number of Participants Who Experienced at Least One AE Related to the Study Drug
timeFrame: Up to Day 56
measure: SCD: Number of Participants Who Experienced at Least One SAE
timeFrame: Up to Day 56
measure: SCD: Number of Participants With Clinically Significant Laboratory Abnormalities, by Severity
timeFrame: Up to Day 56
measure: SCD: Number of Participants With Clinically Significant Changes in Vital Signs and in ECG Parameters
timeFrame: Up to Day 56
Secondary outcomes:
measure: Maximum Observed Concentration (Cmax) of AG-946
timeFrame: SAD: Up to Day 8; MAD: Up to Day 49; SCD: Up to Day 56
measure: Time to Reach Maximum Observed Concentration (Tmax) of AG-946
timeFrame: SAD: Up to Day 8; MAD: Up to Day 49; SCD: Up to Day 56
measure: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC0-t), Time Curve from Time Zero to Infinity (AUC0-∞), and Time Curve from Time Zero to Time tau Over the Dosing Interval (AUC0-τ) for AG-946
timeFrame: SAD: Up to Day 8; MAD: Up to Day 49; SCD: Up to Day 56
measure: SAD: Apparent Clearance (CL/F) for AG-946
timeFrame: SAD: Up to Day 8
measure: SAD: Apparent Volume of Distribution (Vd/F) for AG-946
timeFrame: SAD: Up to Day 8
measure: SAD: Total Amount of Drug Excreted in Urine from Time 0 to Time T (Aet) and from Time t1 to Time t2 (Aet1-t2) for AG-946 Under Fasted and Fed Conditions
timeFrame: Up to Day 3
measure: SAD: Percentage Dose of Drug Excreted in Urine from Time 0 to Time t (fet) and from Time t1 to Time t2 (fet1-t2) for AG-946 Under Fasted and Fed Conditions
timeFrame: Up to Day 3
measure: SAD: Renal Clearance (CLr) for AG-946 Under Fasted and Fed Conditions
timeFrame: Up to Day 3
measure: Changes in the Concentration of 2,3-diphosphoglycerate (2,3-DPG) and Adenosine Triphosphate (ATP) in Whole Blood
timeFrame: SAD: Up to Day 13; MAD: Up to Day 49; SCD: Up to Day 56
measure: Area Under the Effect Curve (AUEC) from Time zero to t for 2,3-DPG and ATP
timeFrame: SAD: Up to Day 13; MAD: Up to Day 49; SCD: Up to Day 56
measure: SAD: Relative Bioavailability Comparing Fasted to Fed Conditions Determined from the PK Parameters of AG-946
timeFrame: SAD: Up to Day 8
measure: SCD: Change From Baseline in Hemoglobin (Hb)
timeFrame: Up to Day 56
measure: SCD: Change From Baseline in Direct Bilirubin
timeFrame: Up to Day 56
measure: SCD: Change From Baseline in Lactate Dehydrogenase (LDH)
timeFrame: Up to Day 56
measure: SCD: Change From Baseline in Haptoglobin
timeFrame: Up to Day 56
measure: SCD: Change From Baseline in Reticulocytes
timeFrame: Up to Day 56
measure: SCD: Change From Baseline in Erythropoietin
timeFrame: Up to Day 56
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: University of California San Diego
state: California
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Boston Medical Center
state: Massachusetts
city: New York
country: United States
facility: New York Presbyterian Hospital - Weill Cornell Medicine
state: New York
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
city: Austin
country: United States
facility: PPD Development, LP
state: Texas
city: Dallas
country: United States
facility: Texas Oncology-Baylor Charles A. Sammons Cancer Center - USOR
state: Texas
city: Houston
country: United States
facility: University of Texas Health Science Center of Houston
state: Texas
city: Copenhagen
country: Denmark
facility: Rigshospitalet, Department of Hematology
city: Barcelona
country: Spain
facility: Hospital Universitario Vall d'Hebron - PPDS
Study officials:
References: